RT Journal Article
SR Electronic
A1 Lederman, Lynne
T1 No Benefit to Adding BEV to Adjuvant CAP in CRC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 36
SP 11
OP 11
DO 10.1177/155989771436006
UL http://mdc.sagepub.com/content/14/36/11.1.abstract
AB Although bevacizumab (BEV) has a role in the treatment of colorectal cancer (CRC), it has not been shown to increase the efficacy of doublet chemotherapy in the adjuvant setting. The final results from the Multicentre International Study of Capecitabine±Bevacizumab as Adjuvant Treatment of Colorectal Cancer [QUASAR 2; ISRCTN45133151], a randomized phase 3 trial that tested capecitabine with and without BEV in the adjuvant setting of stage II/III CRC are discussed in this article.